Substituted aryl piperidinylalkynyladenosines as A2AR agonists

1. A method for treating biological diseases comprising the administration of an effective amount of a suitable antibiotic agent, antifungal agent, or antiviral agent in conjunction with a compound of formula I or a pharmaceutically acceptable salt thereof,

R 1 and R 2 independently are selected from the group consisting of H, (C 1 -C 8 )alky, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 8 )alkylene, aryl, aryl(C 1 -C 8 )alkylene, heteroaryl, heteroaryl(C 1 -C 8 )alkylene-, diaryl(C 1 -C 8 )alkylene, and diheteroaryl(C 1 -C 8 )alkylene, wherein the aryl and heteroaryl rings are optionally substituted with 1-4 groups independently selected from fluoro, chloro, iodo, bromo, methyl, trifluoromethyl, and methoxy;

each R independently is selected from the group consisting of H, C 1 -C 4 alkyl, cyclopropyl, cyclobutyl, and (CH 2 ) a cyclopropyl;

X is CH or N, provided that when X is CH then Z cannot be substituted with halogen, C 1 -C 6 alkyl, hydroxyl, amino, or mono- or di-(C 1 -C 6 -alkyl)amino;

Y is selected from the group consisting of O, NR 1 , —(OCH 2 CH 2 O) m CH 2 —, and —(NR 1 CH 2 CH 2 O) m CH 2 —, provided that when Y is O or NR 1 , then at least one substituent is present on Z;

Z is selected from the group consisting of 5-membered heteroaryl, 6-membered aryl, 6-membered heteroaryl, carbocyclic biaryl, and heterocyclic biaryl, wherein the point of attachment of Y to Z is a carbon atom on Z, wherein Z is substituted with 0-4 groups independently selected from the group consisting of F, Cl, Br, I, (C 1 -C 4 )alkyl, —(CH 2 ) a OR 3 , —(CH 2 ) a NR 3 R 3 , —NHOH, —NR 3 NR 3 , nitro, —(CH 2 ) a CN, —(CH 2 ) a CO 2 R 3 , —(CH 2 ) a CONR 3 R 3 , trifluoromethyl, and trifluoromethoxy;

alternatively, Y and Z together form an indolyl, indolinyl, isoindolinyl, tetrahydroisoquinolinyl, or tetrahydroquinolinyl moiety wherein the point of attachment is via the ring nitrogen and wherein said indolyl, indolinyl, isoindolinyl, tetrahydroisoquinolinyl, or tetrahydroquinolinyl moiety, which is substituted with 0-4 groups independently selected from the group consisting of F, Cl, Br, I, C 1 -C 4 alkyl, —(CH 2 ) a OR 3 , —(CH 2 ) a NR 3 R 3 , —NHOH, —NR 3 NR 3 R 3 , NO 2 , —(CH 2 ) a CN, —(CH 2 ) a CO 2 R 3 , —(Ch 2 ) a CONR 3 R 3 , CF 3 , and OCF 3 ;

R 3 is independently selected from the group consisting of H, (C 1 -C 6 )alkyl, cycloalkyl, aryl, and heteroaryl;

R 4 is selected from the group consisting of CH 2 OR, C(O)NRR, and CO 2 R;

a is selected from 0, 1, and 2;

m is selected from 1, 2, and 3;

n is selected from 0, 1, and 2;

each p independently is selected from 0, 1, and 2; and,

q is selected from 0, 1, and 2.

2. The method of claim 1 , wherein the compound is of formula (Ia) or a pharmaceutically acceptable salt thereof:

3. The method of claim 2 , wherein the compound is of formula (Ib) or a pharmaceutically acceptable salt thereof:

wherein:

each Z′ is independently selected from the group consisting F, Cl, Br, I, C 1 -C 4 alkyl, —(CH 2 ) a OR 3 , —(CH 2 ) a NR 3 R 3 , —NHOH, —NR 3 NR 3 R 3 , NO 2 , —(CH 2 ) a CN, —(CH 2 ) a CO 2 R 3 , —(CH 2 ) a CONR 3 R 3 , CF 3 , and OCF 3 .

4. The method of claim 3 , wherein the compound is of formula (Ic) or a pharmaceutically acceptable salt thereof:

5. The method of claim 4 , wherein Z′ is selected from the group consisting of F, Cl, methyl, OR 3 , NO 2 , CN, NR 3 R 3 and CO 2 R 3 .

6. The method of claim 5 , wherein R 3 is methyl or hydrogen.

7. The method of claim 1 , wherein the compound is selected from the group consisting of Compound Numbers 3, 5-31, and 33-57 shown in Table 1.

8. The method of claim 1 , wherein the compound further includes a pharmaceutically acceptable carrier.